DGX — Quest Diagnostics Incorporated

Quest Diagnostics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Consolidated Revenues: $2.9 billion, up 9.2% year-over-year, primarily driven by organic growth.
• Organic Revenue Growth: 9%, with total volume (requisitions) increasing by 10.9%.
• Adjusted EPS: $2.50, a 13% increase from $2.21 in the prior year.
• Operating Income: Reported at $399 million (13.8% of revenues), with adjusted operating income at $447 million (15.4% of revenues).
• Cash from Operations: $278 million, down from $314 million year-over-year due to timing of receipts and higher bonus payments.

2. Strategic Updates and Business Highlights

• Growth Drivers: Strong demand for clinical innovations, expansion into new clinical areas, and collaborations with health organizations.
• Clinical Innovations: Significant growth in advanced diagnostics, particularly in Alzheimer's testing and cardiometabolic testing.
• Consumer Health: Continued momentum in consumer health initiatives, with robust growth from questhealth.com and partnerships with wellness brands.
• Automation and AI: Increased productivity through automation and AI deployment, including a 40% productivity boost in customer service.
• Project Nova: Ongoing multiyear initiative to transform order-to-cash processes, with expenses expected to ramp up in the second half of 2026.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised to $11.78 billion - $11.9 billion for the year, reflecting a growth rate of 6.8% to 7.8%.
• EPS Guidance: Reported EPS expected between $9.58 and $9.78; adjusted EPS between $10.63 and $10.83.
• Cash from Operations: Projected at approximately $1.75 billion with capital expenditures around $550 million.
• Operating Margin: Expected to expand compared to the previous year.

4. Bad News, Challenges, or Points of Concern

• Cash Flow Decline: Cash from operations decreased year-over-year, attributed to timing and higher bonus payments.
• Revenue per Requisition: Overall revenue per requisition declined by 1.3%, although it increased by 2.5% when excluding the impact of major collaborations with Fresenius and Corewell.
• Weather Impact: Negative weather conditions affected revenues, with a $9 million revenue impact reported.
• Fuel Costs: Anticipated higher fuel costs due to macroeconomic factors, estimated to impact EPS by $0.05 to $0.07.

5. Notable Q&A Insights

• Organic Volume Dynamics: Strong organic volume growth of 10.8%, with contributions from Fresenius and Corewell accounting for about 7%.
• Impact of ACA Subsidies: No significant impact from ACA subsidy changes observed in Q1, though a 30 basis point revenue impact is still embedded in guidance.
• CRUSH Initiative: Management downplayed concerns regarding the CRUSH initiative, stating that Quest is not significantly impacted by the tests under scrutiny.
• Consumer Testing Trends: The convergence of AI, wearables, and consumer-initiated testing is expected to increase longitudinal testing and consumer engagement with health metrics.
• M&A Environment: The M&A funnel remains active, with ongoing interest in health system outreach deals, although no contributions from M&A are included in the current guidance.

Overall, Quest Diagnostics reported a strong first quarter, marked by organic growth and strategic advancements, while navigating challenges related to cash flow and external economic factors. The company remains optimistic about its growth trajectory and strategic initiatives moving forward.